{"entity":{"id":"nct07745790","kind":"trial","name":"Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of sintilimab and tegafur, gimeracil and oteracil (S-1) in pancreatic cancer, run by Ruijin Hospital, not yet recruiting.","summary":"Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer is a phase 2, interventional study registered as NCT07745790 by Ruijin Hospital, with a registry enrolment figure of 20 participants, started 2026-07-13 and due to reach its primary completion in 2029-07-31. Interventions recorded: Multimodal Thermal Therapy (MTT) System; KRAS G12V mRNA Vaccine; Sintilimab; S-1. Conditions listed: Pancreatic Ductal Adenocarcinoma; Liver Neoplasms; Lung Neoplasms. Primary outcome: Incidence and Severity of Adverse Events (CTCAE v6.0); Frequency of Dose Modifications and Treatment Discontinuations. Pancreatic eligibility wording from the registry: \"* Patients with advanced pancreatic cancer or postoperative recurrent pancreatic cancer confirmed by histopathological or cytological examination\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07745790","url":"https://clinicaltrials.gov/study/NCT07745790"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","neoantigen-mrna-vaccine"],"targets":[],"drugs":["sintilimab","tegafur-gimeracil-oteracil"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07745790","phase":"2","setting":"A Study of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab for Safety and Efficacy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Disease Progression After or Are Intolerant to Standard First-Line Therapy","sponsor":"Ruijin Hospital","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07745790/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"drug":[{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"},{"id":"tegafur-gimeracil-oteracil","kind":"drug","name":"Tegafur, gimeracil and oteracil (S-1)","route":"/drugs/tegafur-gimeracil-oteracil/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}